SCHEDULE: Gilde Healthcare Boosts Stake in Shoulder Innovations

Gilde Healthcare has increased its beneficial ownership in Shoulder Innovations, Inc. to 11.8% following the company's initial public offering and conversion of preferred stock.

Summary

• Gilde Healthcare Holding B.V. and its affiliates (the "Reporting Persons") have reported beneficial ownership of 2,380,482 shares of Shoulder Innovations, Inc. Common Stock.
• This represents approximately 11.8% of the Issuer's outstanding Common Stock after the closing of its Initial Public Offering (IPO).
• The Reporting Persons' investment includes the conversion of 33,259,424 shares of Series D convertible preferred stock purchased for $18,000,000 in February and March 2023.
• It also includes the conversion of 10,252,188 shares of Series E convertible preferred stock purchased for $6,999,998 in March 2025.
• Upon the IPO closing on August 1, 2025, these preferred shares automatically converted into Common Stock at a rate of 1-for-0.052410901.
• Additionally, Gilde Healthcare purchased an extra 100,000 shares of Common Stock at $15.00 per share for an aggregate of $1,500,000 in connection with the IPO.
• The total investment by Gilde Healthcare in preferred stock and the IPO common stock purchase amounts to approximately $26,500,000.
• The Reporting Persons hold these securities for general investment purposes and may adjust their holdings based on market conditions and the Issuer's prospects.
• Geoff Pardo, a partner at Gilde Healthcare, serves as a member of the Issuer's board of directors and may receive compensation for his service.

Sentiment

Score: 8

Explanation: The filing indicates a strong positive sentiment. A major healthcare-focused venture capital firm has maintained and increased its significant stake in the company through its IPO, demonstrating continued confidence and a long-term investment horizon. The board representation further solidifies this commitment.

Positives

• A significant investment by Gilde Healthcare, a reputable venture capital firm specializing in healthcare, indicates confidence in Shoulder Innovations, Inc.'s future.
• Gilde Healthcare's partner, Geoff Pardo, holds a board seat, providing direct oversight and strategic input from a major investor.
• The investment is for general investment purposes, suggesting a long-term strategic interest rather than short-term trading.

Negatives

• Gilde Healthcare is subject to a 180-day lock-up agreement, restricting the sale or transfer of its shares post-IPO, which limits liquidity for that period.

Risks

• The Reporting Persons' investment strategy may change, leading to potential increases or decreases in their stake, which could impact share price.
• The value of the investment is subject to general stock market and economic conditions.
• The lock-up agreement restricts the Reporting Persons' ability to sell shares for 180 days, potentially limiting their flexibility to react to market changes during that period.

Future Outlook

The Reporting Persons intend to review their investment in the Issuer on a continuing basis and may decide at any time to increase or decrease the size of their investment in the open market, privately negotiated transactions, or pursuant to 10b5-1 trading plans, depending on various market, economic, and company-specific factors.

Management Comments

• Geoff Pardo, a partner at Gilde Healthcare, serves as a member of the board of directors of the Issuer.
• In his capacity as a director, Mr. Pardo may be entitled to receive cash compensation and equity compensation, including stock options, restricted stock units or other equity awards, pursuant to a plan or policy with regard to compensation of members of the board of directors of the Issuer.

Industry Context

Gilde Healthcare is a venture capital firm focused on investments in companies developing biotechnology, molecular diagnostics, and medical technology products. This investment in Shoulder Innovations, Inc., a medical technology company, aligns directly with Gilde Healthcare's stated investment focus and expertise within the broader healthcare industry.

Comparison to Industry Standards

• The investment by Gilde Healthcare, a specialized healthcare fund, is consistent with typical venture capital firm strategies of taking significant stakes in promising medical technology companies, especially around their IPO stage.
• The 11.8% beneficial ownership stake is a substantial position for an institutional investor, indicating a strong conviction in Shoulder Innovations' market potential, comparable to lead investor positions seen in other medical device or biotech IPOs.
• The lock-up agreement for 180 days is a standard practice for pre-IPO investors and insiders, aligning with industry benchmarks to ensure market stability post-listing.

Corporate Governance

Related Party Transactions

• Geoff Pardo, a partner at Gilde Healthcare, serves as a member of the board of directors of Shoulder Innovations, Inc.
• Mr. Pardo may receive cash and equity compensation (stock options, restricted stock units, or other equity awards) for his service as a director, pursuant to the Issuer's compensation plan or policy.

Stakeholder Impact

• **Shareholders**: Increased institutional ownership by a specialized healthcare fund may be viewed positively, signaling confidence. The lock-up agreement provides temporary stability post-IPO by restricting a large block of shares from being sold.
• **Company (Shoulder Innovations, Inc.)**: The IPO and prior preferred stock investments provided significant capital, supporting operations and growth. Continued board representation by a major investor ensures alignment and strategic guidance.
• **Employees**: No direct impact mentioned, but a well-capitalized company with strong investor backing generally provides a more stable environment.
• **Customers/Suppliers**: No direct impact mentioned, but a financially stable company is better positioned to serve customers and maintain supplier relationships.

Next Steps

• Gilde Healthcare will continue to review its investment in Shoulder Innovations, Inc. on an ongoing basis.
• Potential future acquisitions or dispositions of shares by Gilde Healthcare, depending on market conditions and company performance.
• The 180-day lock-up period for Gilde Healthcare's shares will expire, allowing for potential future transactions.

Key Dates

Recommendation

The filing indicates a significant, long-term investment by a reputable healthcare-focused venture capital firm, Gilde Healthcare, in Shoulder Innovations, Inc. This substantial stake (11.8%) and participation in the IPO suggest confidence in the company's prospects. However, as a Schedule 13D, it primarily details ownership changes and investment intent rather than comprehensive financial performance or strategic updates. Investors should 'hold' and await further financial disclosures (e.g., 10-K/Q filings) to make a more informed decision, while acknowledging the positive signal from Gilde's commitment.

Keywords

Shoulder Innovations, Gilde Healthcare, SEC filing, Schedule 13D, IPO, Common Stock, Preferred Stock, beneficial ownership, medical technology, venture capital, healthcare investment, corporate governance